Literature DB >> 8473716

The effects of nefazodone, imipramine and placebo, alone and combined with alcohol, in normal subjects.

L J Frewer1, M Lader.   

Abstract

Nefazodone (200 mg, 400 mg/day) imipramine (150 mg/day) and placebo were administered to 12 normal, healthy volunteer subjects for a period of 8 days each. A measured dose of alcohol was consumed with the drug on day 8. A battery of physiological, psychomotor, cognitive and subjective tests was carried out before drug administration and 2 h after drug administration on days 1, 7, and 8. Nefazodone had little effect on heart rate and blood pressure whereas imipramine increased both heart rate and diastolic blood pressure. Nefazodone 400 mg impaired the critical flicker fusion threshold. Dose-dependent improvements in psychomotor performance (Gibson Spiral Maze) and complex memory performance (learning, pursuit rotor, and visual working memory) were produced by nefazodone while imipramine administration impaired performance on these tasks. Subjective changes in alertness and bodily symptoms were produced by all active compounds. While nefazodone failed to potentiate the sedative-hypnotic (depressant) effects of alcohol, imipramine tended to enhance them for psychomotor performance, memory assessments, and some subjective ratings. Thus, nefazodone, particularly at lower dose levels, causes less disruption of human performance than imipramine. This effect probably reflects the lack of anticholinergic activity of nefazodone. Also, nefazodone failed to potentiate the depressant effects of alcohol, perhaps because of its minimal alpha-blockade.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8473716     DOI: 10.1097/00004850-199300810-00002

Source DB:  PubMed          Journal:  Int Clin Psychopharmacol        ISSN: 0268-1315            Impact factor:   1.659


  7 in total

Review 1.  Antidepressant use in the elderly. Current status of nefazodone, venlafaxine and moclobemide.

Authors:  R J Goldberg
Journal:  Drugs Aging       Date:  1997-08       Impact factor: 3.923

Review 2.  Clinical pharmacokinetics of nefazodone.

Authors:  D S Greene; R H Barbhaiya
Journal:  Clin Pharmacokinet       Date:  1997-10       Impact factor: 6.447

3.  Effects of acute and chronic antidepressant treatments on memory performance: a comparison between paroxetine and imipramine.

Authors:  Laurent Naudon; Maïté Hotte; Thérèse M Jay
Journal:  Psychopharmacology (Berl)       Date:  2007-01-12       Impact factor: 4.530

4.  Modelling the cost effectiveness of antidepressant treatment in primary care.

Authors:  D A Revicki; R E Brown; W Palmer; D Bakish; W W Rosser; S F Anton; D Feeny
Journal:  Pharmacoeconomics       Date:  1995-12       Impact factor: 4.981

Review 5.  Biomarkers for the effects of selective serotonin reuptake inhibitors (SSRIs) in healthy subjects.

Authors:  G J H Dumont; S J de Visser; A F Cohen; J M A van Gerven
Journal:  Br J Clin Pharmacol       Date:  2005-05       Impact factor: 4.335

Review 6.  Nefazodone. A review of its pharmacology and clinical efficacy in the management of major depression.

Authors:  R Davis; R Whittington; H M Bryson
Journal:  Drugs       Date:  1997-04       Impact factor: 9.546

Review 7.  Behavioural toxicity of medicinal drugs. Practical consequences, incidence, management and avoidance.

Authors:  J G Ramaekers
Journal:  Drug Saf       Date:  1998-03       Impact factor: 5.606

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.